People taking a certain targeted medication for advanced lung cancer may soon spend much less time receiving treatment. The U.S. Food and Drug Administration (FDA) has approved a new formulation of amivantamab (Rybrevant) that can be given as an injection in about five minutes. This represents a significant change from the multihour infusion, which had been standard previously.

Thanks! You've successfully submitted your vote.

Sign up to view the results!

Continue with Facebook

Continue with Google

Continue with your email

By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.

Already a Member? Log in

The new option, called Rybrevant Faspro, is approved for people with locally advanced or metastatic non-small cell lung cancer (NSCLC) that tests positive for epidermal growth factor receptor (EGFR) mutations. Rybrevant Faspro combines amivantamab with hyaluronidase-lpuj.

What Is Rybrevant?

Rybrevant is a targeted therapy used to treat certain lung cancers with mutations (changes) in the EGFR gene. These mutations help drive cancer growth in some people with NSCLC. EGFR mutations are present in 10 percent to 15 percent of lung cancers in Americans.

Until now, Rybrevant was given through an intravenous (IV) infusion, which can take several hours in a clinic or infusion center.

What’s Different About the New Injection?

Rybrevant Faspro is given as a subcutaneous injection, meaning it’s injected under the skin rather than into a vein. According to the FDA approval, this reduces administration time from several hours to approximately five minutes.

In addition to amivantamab, the drug contains an added enzyme called hyaluronidase-lpuj that helps the medication absorb under the skin. In clinical studies, people had fewer reactions during treatment with the injection than with the IV infusion.

What Did the Study Show?

The FDA approval was based on results from a phase 3 study that showed Rybrevant Faspro delivered similar drug levels in the body compared to the IV formulation. This means the faster injection worked in a way that was consistent with standard Rybrevant treatment.

The approval applies to all current indications of Rybrevant, giving people and healthcare teams another way to receive the same medication.

What Kind of Side Effects Does It Cause?

Like the IV version, Rybrevant Faspro can cause side effects. Commonly reported side effects include:

• Rash
• Nail changes
• Muscle or joint pain
• Fatigue
• Mouth sores
• Edema (swelling)
• Nausea, diarrhea, vomiting, or constipation
• Reduced appetite
• Headache

Changes in blood test results are also common.

Rare but serious side effects may include:

• Severe allergic reactions
• Pneumonitis (lung inflammation)
• Severe skin reactions
• Eye problems
• Increased risk of blood clots

Why This Matters for People With NSCLC

Shorter treatment times may reduce the burden of frequent clinic visits and make care more manageable for some people living with advanced lung cancer. As always, your healthcare provider can help determine which treatment option is most appropriate for your specific diagnosis.

Join the Conversation

On MyLungCancerTeam, members share their experiences with lung cancer, get advice, and find support from others who understand.

Are you currently receiving infusions as part of your lung cancer treatment? Let others know in the comments below.